ImmuPharma presents Lupuzor’sTM Phase IIb data at leading medical congress, the 2012 American College of Rheumatology Meeting, Washington, D.C.

20th November 2012 - 9:22 am

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to today outline the key abstract information presented on Wednesday 14 November at the 2012 Annual American College of Rheumatology (“ACR”) Meeting which was held this week. The ACR Annual Scientific Meeting is the premier worldwide scientific meeting devoted to rheumatic diseases and is attended by key opinion leaders and medical practicioners as well as scientific staff and pharmaceutical companies.  The title of the session was called “Systemic Lupus Erythematosus – Clinical Aspects and Treatment”.

The presentation was given by the authors of the abstract:  ImmuPharma’s President and Chief Science Officer Dr. Robert Zimmer, together with Daniel J. Wallace, Associate Director, Rheumatology Fellowship Program, Cedars-Sinai Medical Center, Los Angeles, a leading practicioner within the field of Lupus and Sylviane Muller, Research Director at CNRS, Strasbourg, France, who was the key inventor of Lupuzor. (Full biographies can be found in ‘Notes to Editors’).
Lupus is an autoimmune disease which involves the immune system of the patient targeting multiple organs, with recurrent flares causing a progressive level of damage and disability – the disease is clinically heterogeneous (or of varying nature) in its basis which makes diagnosis difficult. The condition is often misdiagnosed in the beginning as rheumatoid arthritis. According to the US Lupus Foundation, it affects up to 1.5m individuals in the US alone.
The multicenter, randomized, placebo-controlled phase IIb study of Lupuzor™ (P140 with Mannitol as stabilizer) run by ImmuPharma in patients with Lupus (a dose of 200µg / month in addition to “standard of care” vs “standard of care” alone), including patients with clinical SLEDAI-2K scores above 6 and no Bilag A score.  Efficacy was evaluated using the SRI score.
Share this article